Literature DB >> 31348081

Influence of Biological Parameters Assessed in [18F]FDG PET/CT on Overall Survival in Cervical Cancer Patients.

Paulina Cegla1, Ewa Burchardt2, Andrzej Roszak2,3, Rafal Czepczynski4, Anna Kubiak5, Witold Cholewinski1,3.   

Abstract

AIM: The aim of this study was to estimate the influence of biological parameters assessed in [F]FDG PET/CT on overall survival (OS) in cervical cancer patients.
METHODS: Retrospective analysis was performed on a group of 371 patients with newly diagnosed and histologically confirmed cervical cancer. PET biological parameters in primary tumor including SUVmax, SUVmean, total lesion glycolysis (TLG), metabolic tumor volume (MTV), heterogeneity, and parameters referring both to primary tumor and metastatic lesions: SUVtotal, TLGtotal, and MTVtotal, were analyzed.
RESULTS: Based on PET/CT results, 3 subgroups were identified: cervical only-with disease limited only to the cervix (38%), +regional nodes-where increased glucose accumulation in addition to the cervical area was also observed in regional lymph nodes (36%), and +distal metastases-where PET scan showed a disseminated disease (26%). Depending on the stage of the disease, in the cervical-only group, 5-year survival rate was 86%; in the +regional nodes group, it was 80%; whereas in the +distal metastases group, 5-year survival rate was only 55%. However, based on Cox regression model, significant influence on OS was found only in heterogeneity of primary tumor; more inhomogeneous tumors suggest worse prognosis (0.25 ± 0.04 vs 0.16 ± 0.09, P < 0.001), SUVtotal (76.6 ± 130.1 vs 45.4 ± 73.4, P = 0.002), and MTVtotal (79.03 ± 88.27 vs 63.00 ± 83.80 cm, P = 0.03). For heterogeneity, cutoff point suggesting worse prognosis was 0.18; for SUVtotal, 52.3; and for MTVtotal, 66.55 cm.
CONCLUSIONS: Stage of disease assessed in [F]FDG PET/CT significantly influences survival rate in patients with cervical cancer. SUVtotal, MTVtotal, and heterogeneity of primary tumor are independent prognostic factors on OS in cervical cancer patients.

Entities:  

Mesh:

Substances:

Year:  2019        PMID: 31348081     DOI: 10.1097/RLU.0000000000002733

Source DB:  PubMed          Journal:  Clin Nucl Med        ISSN: 0363-9762            Impact factor:   7.794


  6 in total

1.  18F-FDG PET/CT in diagnostic and prognostic evaluation of patients with cardiac masses: a retrospective study.

Authors:  Chunxia Qin; Fuqiang Shao; Fan Hu; Wenyu Song; Yangmeihui Song; Jinxia Guo; Xiaoli Lan
Journal:  Eur J Nucl Med Mol Imaging       Date:  2019-12-05       Impact factor: 9.236

2.  Receptor for activated C kinase 1 promotes cervical cancer lymph node metastasis via the glycolysis‑dependent AKT/mTOR signaling.

Authors:  Lixiu Xu; Jinqiu Li; Mikrban Tursun; Yan Hai; Hatila Tursun; Batur Mamtimin; Ayshamgul Hasim
Journal:  Int J Oncol       Date:  2022-05-26       Impact factor: 5.884

3.  LINC00997/MicroRNA 574-3p/CUL2 Promotes Cervical Cancer Development via Mitogen-Activated Protein Kinase Signaling.

Authors:  Daming Chu; Tengteng Liu; Yuan Yao; Nannan Luan
Journal:  Mol Cell Biol       Date:  2021-07-23       Impact factor: 4.272

4.  Lipid metabolism regulator human hydroxysteroid dehydrogenase-like 2 (HSDL2) modulates cervical cancer cell proliferation and metastasis.

Authors:  Yang Yang; Anna Han; Xinyue Wang; Xianglin Yin; Minghua Cui; Zhenhua Lin
Journal:  J Cell Mol Med       Date:  2021-03-18       Impact factor: 5.310

5.  Prognostic value of 11C-methionine volume-based PET parameters in IDH wild type glioblastoma.

Authors:  Bart R J van Dijken; Alfred O Ankrah; Gilles N Stormezand; Rudi A J O Dierckx; Peter Jan van Laar; Anouk van der Hoorn
Journal:  PLoS One       Date:  2022-02-25       Impact factor: 3.240

6.  Searching for the methylation sites involved in human papillomavirus type 16 and 18‑positive women with cervical cancer.

Authors:  Yanyun Ma; Chunxia Wang; Mengqi Shi; Mingshan Li; Lin Li; Tuanjie Che; Jing Qu
Journal:  Mol Clin Oncol       Date:  2022-09-02
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.